Friday, April 08, 2016
MedDay Secures €34 Million ($38.5M) New Funding
Edmond de Rothschild Investment Partners led the Series B financing alongside existing investors Sofinnova Partners and InnoBio. Large Venture also participated in the operation.
Funds will drive a confirmatory phase 3 study in US to treat progressive multiple sclerosis with MedDay’s wholly-owned lead candidate, MD1003
The drug is already commercialized in some European countries under “named patient use”.
Users browsing this forum: No registered users